Natixis’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Natixis’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-20,443	Closed	-$234K	–	1376
2017 Q3	$234K	Buy	+20,443	New	+$215K	﹤0.01%	1040

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Natixis's MACK Position: Q4 2017 in Review

Natixis sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2017, closing a stake of 20,443 shares — an estimated $234K sold.

Natixis first reported a position in MACK in Q3 2017 and held it in 1 quarter. The position peaked at $234K in Q3 2017. 78 funds tracked by Wall St. Rank hold MACK as of Q4 2017.

Natixis reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Natixis sold 20,443 Merrimack Pharmaceuticals, Inc. shares in Q4 2017, an estimated $234K.
Natixis first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
Natixis's Merrimack Pharmaceuticals, Inc. position peaked at $234K in Q3 2017.
78 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2017.

Based on Natixis's 13F filing for Q4 2017, filed 14 Feb 2018.